arrow
M

Marina Bagnoli

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:29
被引数:2,892

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial

肿瘤浸润性白细胞作为接受贝伐珠单抗治疗的卵巢癌患者的预后生物标志物:来自IV期MITO16A/MaNGO OV-2临床 trial 的结果

2025-11-170
OAAI
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
2025-01-011
OAAI
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial
2023-04-112
OAAI
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab
2022-08-312
OAAI
Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment

基于microRNA的早期上皮性卵巢癌早期复发预测因子MiROvaR作为优化患者预后评估的新策略的验证

2022-01-014
PRE
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
CELLS
IF5.2
2019-02-267
OAAI
Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth

E-cadherin和PLEKHA7同时表达对e-cadherin/EGFR介导的卵巢癌细胞生长有负面影响

2018-07-1125
OAAI
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer

MiR-506抑制上皮-间质转化网络中的多个靶点并与上皮性卵巢癌的良好预后相关

2014-11-06102
OAAI
Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer (vol 5, pg 707, 2013)
2014-02-072
OAAI